Clene Inc.
CLNNConsumer DefensiveNASDAQPackaged Foods · Last scanned Oct 24, 2026
Scan Results
Daily timeframePart of the consumer defensive sector, Clene Inc. (CLNN) is listed under Packaged Foods. At a $55.2M market cap, Clene Inc. ranks as a micro-cap company within consumer defensive. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
Market Cap
$55.2M
Beta
0.92
P/E (TTM)
—
P/E (Fwd)
-1.59
EPS (TTM)
$-3.52
EPS (Fwd)
$-2.44
ROE
—
ROA
-56.9%
Cash
$9.7M
Total Debt
$22.3M
Free CF
-$9.9M
52W Change
-53.5%
Annual Financials
Cash vs Debt
Where CLNN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CLNN finished 38.50% below its 150-day moving average ($5.35) and 37.57% below its 200-day moving average ($5.27). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CLNN overbought or oversold?
At the October 20, 2026 close, CLNN's RSI(14) was 21.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, CLNN has $9.7M in cash with $22.3M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$9.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has pulled back from $473K (2022) to $200K (2025), a 58% decline worth watching.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing CLNN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.